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Abstract Fusion proteins between the human A1 adenosine
receptor and the pertussis toxin resistant (Cys351Gly) mutant of
the G-protein K subunit Gi1K (A1/Gi), and between the human A1
adenosine receptor, the Aequorea victoria green fluorescent
protein (GFP) and Cys351Gly Gi1K (A1/GFP/Gi), were
expressed in CHO cells. The agonist NECA caused a stimulation
of [35S]GTPQS binding at both fusion proteins with similar
concentration dependence as at the native receptor. However in
the presence of pertussis toxin NECA stimulation of [35S]GTPQS
binding was only seen at the A1/GFP/Gi fusion protein. The
regulation of the adenylyl cyclase and MAP kinase effector
systems by both fusion proteins was attenuated following
pertussis toxin treatment. These studies demonstrate for the
first time the characterisation of a fusion protein between a G-
protein coupled receptor, GFP and a G-protein K subunit.
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1. Introduction
The human A1 adenosine receptor couples to members of
the Gi=oK family of heterotrimeric G-proteins to cause the
inhibition of adenylyl cyclase, the stimulation of phoshoino-
sitidase C, the activation of inwardly rectifying K channels
and the inhibition of neuronal calcium channels [1^3]. With
the exception of GzK each of these G-proteins can be modi¢ed
by pertussis toxin catalysed transfer of an ADP-ribose moiety
onto a cysteine residue four amino acids from the C-terminus,
to result in the attenuation of receptor coupling [4]. To study
receptor coupling through a single G-protein we and others
have generated mutant G-proteins in which this cysteine res-
idue has been mutated to a serine [4] or glycine [5,6] and have
included these mutant G-proteins into G-protein coupled re-
ceptor (GPCR)/G-protein fusions. Transient expression of
such fusion proteins has demonstrated that the receptor can
couple to both endogenous and fused G-protein and that the
rank order of agonist e⁄cacy is maintained when studying
signalling through the fused G-protein [7^10].
Many reports describe the fusion of the Aequorea victoria
green £uorescent protein (GFP) to the C-terminus of a
GPCR. Such fusion proteins have been used to study receptor
tra⁄cking and agonist-mediated desensitisation and internal-
isation. In such studies an intrinsically £uorescent receptor is
created with ligand binding a⁄nity, signalling speci¢city and
phosphorylation and internalisation characteristics, which ap-
pear indistinguishable from the wild-type receptor [11^13].
In the present study we have combined the features of
GPCR/G-protein and GPCR/GFP fusion proteins by gener-
ating a receptor/GFP/G-protein fusion. Fusion proteins con-
sisting of the human A1 adenosine receptor and the pertussis
toxin resistant (Cys351Gly) mutant of rat Gi1K (A1/Gi), and
between the human A1 adenosine receptor, GFP, and the
Cys351Gly mutant of rat Gi1K (A1/GFP/Gi) have been char-
acterised following stable expression in CHO cells. We dem-
onstrate that GFP may be included in a receptor/G-protein
fusion with little e¡ect upon the behaviour of the chimeric
protein.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium/nutrient mix F12 (50:50)
(DMEM/F12), foetal calf serum (FCS), glutamine and neomycin
(G418) were from Life Technologies. NECA (5P-N-ethylcarboxami-
doadenosine) was purchased from Research Biochemical International
and adenosine deaminase from Boehringer Mannheim. Forskolin, 3-
isobutyl-1-methylxanthine (IBMX) and all other chemicals were pur-
chased from Sigma. Scintillation proximity assay (SPA) beads and
[35S]GTPQS (1175 Ci/mmol) were purchased from Amersham.
[3H]DPCPX (8-cyclopentyl-1,3-dipropylxanthine) (120 Ci/mmol) was
from New England Nuclear.
2.2. Construction and expression of A1 adenosine receptor fusion
proteins
A human codon optimised GFP was ampli¢ed by PCR from
pEGFP (Clontech) using oligonucleotides 5P-AATCCATGGTGAG-
CAAGGGCGAGGAG (sense) and 5P-AATCCATGGTGTACAG-
CTCGTCCATGCCGAGAG (antisense) (NcoI restriction sites under-
lined). During ampli¢cation the GFP stop codon was removed. The
PCR product was gel puri¢ed and subcloned into pCR-script (Stra-
tagene). GFP was released from this vector by digestion with NcoI
and ligated with similarly digested pCR-script/A1/Gi [10] to generate
A1/GFP/Gi. For expression A1/Gi and A1/GFP/Gi were subcloned
into the EcoRI sites of pCIN [14] and pcDNA3 (Invitrogen).
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All cells were maintained in 5% CO2 at 37‡C. HEK 293/T cells,
grown to 60^80% con£uence in 60 mm culture dishes in DMEM
containing 10% FCS and 2 mM L-glutamine, were transfected with
pcDNA3 containing either the A1 receptor, or the A1/Gi or A1/GFP/
Gi fusions using LipofectAMINE (Life Technologies) [8]. Following
transfection, growth medium was supplemented with adenosine deam-
inase (2 U/ml). Cells were harvested 48 h after transfection and stored
as a cell paste at 380‡C. P2 particulate fractions were prepared as
described [4].
Chinese hamster ovary (CHO) cells, maintained in DMEM/F12
containing 5% FCS and 2 mM L-glutamine (growth media), were
transfected with pCIN containing either A1/Gi or A1/GFP/Gi using
the calcium phosphate transfection kit (Invitrogen). Following selec-
tion in 1 mg/ml G418 clones were selected according to the level of
speci¢c [3H]DPCPX binding. CHO cells stably expressing the human
A1 adenosine receptor were previously generated at Glaxo Wellcome.
For studies using pertussis toxin, 50 ng/ml was added to the culture
media 18 h prior to harvesting or assay.
2.3. Immunological studies
Antiserum 64 was produced in a New Zealand White rabbit, using
a conjugate of a synthetic peptide encoding amino acids 149^158 of
the human A1 adenosine receptor and keyhole-limpet haemocyanin
(Calbiochem) as antigen. Membrane samples from transfected cells
(10 Wg) were resolved by SDS-PAGE using a 4^12% (w/v) acrylamide
NuPAGE system (Novex). Following electrophoresis, proteins were
subsequently transferred to nitrocellulose, probed with antiserum 64
at 1:1000 dilution and visualised by enhanced chemiluminescence
(Supersignal, Pierce).
2.4. Membrane preparations
Cells were harvested in PBS containing 5 mM EDTA and homo-
genised in 50 mM HEPES, 10 mM MgCl2 and 1 mM EDTA, pH 7.4,
containing 1 U/10 ml adenosine deaminase. After pelleting at
48 000Ug membranes were resuspended in bu¡er containing 1 U/ml
adenosine deaminase and stored at 380‡C.
2.5. [3H]DPCPX binding
Thawed membrane preparations were pelleted by centrifugation at
100 000Ug for 20 min and resuspended by Dounce homogenisation
(20 strokes) on ice in assay bu¡er (50 mM Tris-HCl, pH 8.26 at 4‡C,
10 mM MgCl2 and 1 mM EDTA, 1 U/ml adenosine deaminase) to
yield a membrane protein concentration of approximately 0.02 mg/ml.
150 Wl of membrane suspension was added to glass tubes containing
50 Wl of [3H]DPCPX (0.25^8 nM) and 50 Wl of either water or 250 WM
R-PIA ([R]-N6-phenylisopropyladenosine) to de¢ne non-speci¢c bind-
ing. Duplicate samples were used for each point. Assays were incu-
bated at 37‡C for 60 min and terminated by rapid ¢ltration over 0.3%
(v/v) polyethylenimine-soaked GF/B ¢lters and washing with ice-cold
assay bu¡er supplemented with 0.01% (w/v) CHAPS using a Brandel
cell harvester. Five ml scintillation £uid was added to each ¢lter disc
and samples were counted following shaking and overnight incubation
at 4‡C. Saturation binding data were analysed using a computer-as-
sisted curve-¢tting package (Prism, Graphpad).
2.6. [35S]GTPQS binding
Assays were performed exactly as described in [10].
2.7. cAMP assays
Cells were seeded into 96-well plates and maintained for 24 h in
growth media. Cells were washed with PBS and incubated with 300
WM IBMX with 1 U/ml adenosine deaminase for 30 min at 37‡C prior
to being stimulated with forskolin (30 WM) and NECA (0.0003^10
WM) for 15 min. The rest of the assay was performed as in [15].
2.8. MAP kinase activity assay
Cells were grown to subcon£uence in 60 mm diameter cell culture
dishes. The media were removed, the cells washed twice with PBS, and
quiescence media (DMEM/F12, 2 mM glutamine, 1 U/ml adenosine
deaminase) added 24 h prior to assay. Cells were stimulated with
NECA (10 WM) for 15 min and MAP kinase activity assays were
performed as described in [15].
2.9. Confocal laser scanning microscopy
Cells, plated on sterile glass coverslips 2 days before the experiment,
were washed with PBS and ¢xed for 20 min by 4% paraformaldehyde
in PBS/5% sucrose, pH 7.2 at room temperature. Fixed cells were
washed twice with PBS/10 mM glycine and mounted on microscope
slides with 40% glycerol in PBS. Cells were observed using a laser
scanning confocal microscope (Zeiss Axiovert 100) using a Zeiss
Plan-Apo 63U1.40 NA oil immersion objective and an electronic
zoom 3. GFP was excited using a 488 nm argon/krypton laser and
detected with 515^540 nm band pass ¢lter. The images were manipu-
lated with Zeiss LSM or Metamorph software.
3. Results
3.1. Expression of A1/Gi and A1/GFP/Gi fusion proteins in
CHO cells
The construction of the fusion protein between the human
A1 adenosine receptor and rat Cys351Gly Gi1K (A1/Gi) is
described in [10]. We now report the construction of a fusion
protein between this receptor, GFP, and rat Cys351Gly Gi1K
(A1/GFP/Gi). To facilitate construction of this fusion the C-
terminal amino acid of the receptor has been changed from
aspartic acid to alanine and the C-terminal amino acid of
GFP from lysine to threonine. Expression of the A1 receptor,
and the A1/Gi and A1/GFP/Gi fusions, as polypeptides of the
expected molecular weights of 49, 79 and 115 kDa, was con-
¢rmed by immunoblotting membranes of transfected HEK
293/T cells with an antiserum raised to the second extracellu-
lar loop of the receptor (Fig. 1).
For characterisation the A1/Gi and A1/GFP/Gi fusions
were stably expressed in CHO cells. The level of receptor
expression was assessed by speci¢c binding of the antagonist
radioligand [3H]DPCPX and cell lines expressing the fusions
at similar receptor densities were identi¢ed (A1/Gi, 5.13 þ 1.26
pmol/mg protein and A1/GFP/Gi, 4.03 þ 0.59 pmol/mg pro-
tein) (Table 1). The Kd for the interaction between
[3H]DPCPX and the fusions was comparable to the Kd for
the interaction of this ligand with the native receptor (Table
1). No speci¢c binding of [3H]DPCPX was observed in mem-
branes from cells transfected with pCIN alone (data not
shown).
The inclusion of GFP within the fusion allows for protein
visualisation by confocal microscopy (Fig. 2). The fusion is
located on cytoplasmic membranes and at the plasma mem-
brane. Cytoplasmic £uorescence represents protein being syn-
Fig. 1. Expression of A1 adenosine receptor and the A1/Gi and A1/
GFP/Gi fusion proteins. HEK 293/T cells were mock transfected
(lane 1), transfected with the human A1 adenosine receptor (lane 2),
the A1/Gi fusion (lane 3) or the A1/GFP/Gi fusion (lane 4). P2 par-
ticulate fractions were prepared as described in Section 2 and 10 Wg
of protein were resolved by SDS-PAGE and immunoblotted with
A1 adenosine receptor-speci¢c antiserum 64. (* denotes Cys351Gly
variant of Gi1K.)
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thesised in the endoplasmic reticulum and being tra⁄cked
through the Golgi apparatus.
3.2. Functional activity of the A1/Gi and A1/GFP/Gi fusion
proteins in CHO cells
Ligand stimulation of the human A1 adenosine receptor
and the fusions was examined by determining the ability of
the agonist NECA to promote the binding of [35S]GTPQS to
Gi G-proteins in membranes prepared from the stable cell
lines. Agonist activity was studied in naive membranes to
examine receptor interaction with endogenous G-protein and
in membranes prepared from cells treated with pertussis toxin
to examine receptor interaction with the fused G-protein. In
the absence of pertussis toxin NECA caused a concentration
dependent increase in [35S]GTPQS binding (Fig. 3A). This was
concentration dependent with EC50 values of 0.73 (0.5^1) nM
(A1 receptor), 2.22 (1.5^3.37) nM (A1/Gi) and 17 (16^19) nM
(A1/GFP/Gi) (Fig. 3A). The placement of the agonist curves
is consistent with the levels of expression determined by sat-
uration binding analysis (A1sA1/GisA1/GFP/Gi). Mem-
branes prepared from cells transfected with the A1 receptor
displayed an elevated basal level of [35S]GTPQS binding sug-
gesting constitutive activity in these cells in which the receptor
is expressed at 12.96 pmol/mg (Table 1). The addition of
NECA to membranes prepared from pertussis toxin treated
cells expressing either the A1 receptor or A1/Gi no longer
caused the stimulation of [35S]GTPQS binding (Fig. 3B). How-
ever, in membranes prepared from similarly treated cells ex-
pressing A1/GFP/Gi NECA was able to promote the binding
of [35S]GTPQS with an EC50 of 257 (193^344) nM.
We next examined the ability of each fusion to regulate
adenylyl cyclase. In the absence of pertussis toxin NECA in-
hibited forskolin stimulated cAMP accumulation in the three
cell lines (Fig. 4A). This was concentration dependent with
Table 1
Expression levels of the human A1 adenosine receptor and the A1/
Gi and A1/GFP/Gi fusions in the stable CHO cell lines
Cell line Bmax (pmol/mg protein) Kd (nM)
A1 12.96 þ 2.23 7.32 þ 0.68
A1/Gi 5.13 þ 1.26 2.30 þ 0.28
A1/GFP/Gi 4.03 þ 0.59 4.21 þ 0.87
Kd and Bmax parameters were obtained from saturation binding
studies using the antagonist [3H]DPCPX. Values are presented as
mean þ S.D. from three separate experiments.
Fig. 2. Cellular distribution of the A1/GFP/Gi fusion protein in
CHO cells. CHO cells stably expressing the A1/GFP/Gi fusion con-
struct were imaged in the confocal microscope as described in Sec-
tion 2.
Fig. 3. NECA stimulation of [35S]GTPQS binding to CHO cell mem-
branes. NECA stimulation of [35S]GTPQS binding was assessed on
membranes prepared from CHO cells stably transfected with the A1
adenosine receptor (m), the A1/Gi fusion (s) and the A1/GFP/Gi fu-
sion (n), in the absence (A), and in the presence (B), of pre-treat-
ment for 18 h with 50 ng/ml pertussis toxin. All values are ex-
pressed as the mean percent of the maximum NECA response (in
the absence of pertussis toxin) of at least three separate experiments
performed in duplicate ( þ S.E.M.).
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IC50 values of 26 (19^27) nM (A1 receptor), 68 (38^123) nM
(A1/Gi) and 54 (20^144) nM (A1/GFP/Gi). Following pertus-
sis toxin treatment NECA was not able to inhibit forskolin
stimulated cAMP indicating that the regulation of adenylyl
cyclase is due to receptor, or fusion protein, coupling to en-
dogenous G-proteins (Fig. 4B).
Many GiK coupled GPCRs have been shown to activate the
MAP kinase cascade [10]. This signalling event is thought to
be mediated by the G-protein LQ complex as it can be blocked
following overexpression of the LQ sequestering proteins K-
transducin or the C-terminus of the L-adrenergic receptor ki-
nase [17]. In the absence of pertussis toxin, the exposure of
CHO cells expressing the human A1 receptor, or either fusion
protein, to 10 WM NECA resulted in a rapid activation of
MAP kinase. In each case this e¡ect was abolished following
pre-treatment with pertussis toxin (Fig. 5).
4. Discussion
To study the interaction of GPCRs with individual GKi G-
proteins we [4] and others [5,6] have mutated the C-terminal
cysteine residue in these G-proteins to render them insensitive
to pertussis toxin catalysed ADP-ribosylation. The incorpora-
tion of such G-proteins into receptor/G-protein fusion pro-
teins allows the study of receptor interaction with individual
G-proteins following pertussis toxin treatment to inactivate
the cellular complement of Gi G-proteins. We have used
this approach to examine the rank order of e⁄cacy of 40
agonists and partial agonists at fusion proteins between the
human A1 adenosine receptor and pertussis toxin insensitive
Gi1K, Gi2K, Gi3K and GoK. Using the [35S]GTPQS binding
assay we showed that the rank order of e⁄cacy was main-
tained at each fusion construct although the absolute poten-
cies were 2^3-fold right shifted compared to ligand e⁄cacy at
the receptor when coexpressed with the pertussis toxin insen-
sitive G-protein [10].
In a parallel series of studies a number of manuscripts have
described the functional expression of GPCR/GFP fusion pro-
teins. The creation of intrinsically £uorescent receptors has
facilitated the study of receptor tra⁄cking, desensitisation
and internalisation [11^13]. The fusion of GFP to the C-ter-
minus of the receptor appears to have little e¡ect on ligand
binding or e¡ector regulation.
The aim of this study was to characterise a fusion protein
between the human A1 adenosine receptor, GFP and rat GilK.
This would permit the study of receptor interaction with a
speci¢c G-protein while also allowing the direct visualisation
of the cellular distribution of the fusion. For functional char-
acterisation the A1/Gi fusion described in [10] and the A1/
GFP/Gi fusion described herein were stably expressed in
Fig. 4. NECA inhibition of forskolin stimulated cAMP accumula-
tion in CHO cells expressing the fusion proteins. NECA inhibition
of forskolin stimulated cAMP accumulation in CHO cells stably ex-
pressing the human A1 adenosine receptor (m), and the A1/Gi (s),
and A1/GFP/Gi fusion proteins (n) in the absence (A), and in the
presence (B), of pre-treatment for 18 h with 50 ng/ml pertussis tox-
in. All values are expressed as the mean percentage of the forskolin
response of three separate experiments performed in quadruplicate
( þ S.E.M.).
Fig. 5. NECA stimulation of MAP kinase in CHO cells expressing
the fusion proteins. NECA activation of MAP kinase in CHO cells
stably expressing the human A1 adenosine receptor, or the A1/Gi or
A1/GFP/Gi fusion proteins. Cells were treated with NECA (10 WM)
for 15 min in the absence (light grey bars) and presence (dark grey
bars) of pre-treatment for 18 h with 50 ng/ml pertussis toxin. Basal
activity in the absence (white bar) and presence (black bar) of per-
tussis toxin is also shown. Bars are the mean percentage of NECA
activation in the absence of pertussis toxin for three separate experi-
ments performed in duplicate ( þ S.E.M.).
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CHO cells at similar receptor densities (Table 1). Saturation
binding analysis indicated that the inclusion of GFP does not
e¡ect the ligand binding characteristics of the fusion (Table 1)
and confocal microscopy indicated that the protein was found
on both internal membranes and at the plasma membrane
(Fig. 2).
The ability of the receptor within each fusion to interact
with cellular and fused G-protein was examined by determin-
ing the ability of the agonist NECA to stimulate high a⁄nity
[35S]GTPQS binding in membranes from transfected cells.
NECA promoted high a⁄nity [35S]GTPQS binding at both
fusion proteins with similar concentration dependence (Fig.
3), demonstrating that in the stable cell lines the receptor in
both fusions is capable of interaction with endogenous G-
protein. Following pertussis toxin treatment the receptor in
the A1/Gi fusion is no longer able to regulate the fused G-
protein. This is in contrast to our previous observations in
which this fusion, transiently expressed in HEK 293/T cells
at 9.6 pmol/mg, remains able to activate the fused G-protein
in the presence of pertussis toxin [10]. The G418 resistant pool
of cells from which the A1/Gi clone was isolated had a level of
expression of 12 pmol/mg. In membranes prepared from this
pool NECA was able to promote high a⁄nity [35S]GTPQS
binding in the presence of pertussis toxin (data not shown).
It appears that to demonstrate functional interaction between
the receptor and G-protein in the A1/Gi fusion requires a level
of expression greater than 5.13 pmol/mg.
In the presence of pertussis toxin NECA remained able to
stimulate high a⁄nity [35S]GTPQS binding at A1/GFP/Gi. At
this fusion the EC50 for activation of the fused G-protein is
15-fold less potent than for the activation of endogenous G-
protein (Fig. 3). This is consistent with previous observations
demonstrating that the potency of agonist activation of (Cys-
351Gly) Gi1K by the porcine K2A-adrenoceptor is 10-fold
lower than that for wild-type Gi1K [10]. It is intriguing that
the receptor in this fusion is able to stimulate the binding of
[35S]GTPQS to the fused G-protein in the presence of pertussis
toxin (Fig. 3). This may indicate that there is some constraint
on receptor/G-protein interaction within these fusions which
is relieved by the inclusion of GFP, acting as a spacer mole-
cule, between the receptor and G-protein.
In the absence of pertussis toxin NECA inhibition of for-
skolin stimulated cAMP accumulation (Fig. 4) and activation
of MAP kinase (Fig. 5), at the wild-type receptor and the
receptor within both fusions, occurred with very similar con-
centration dependence. In the presence of pertussis toxin both
signalling events were abolished indicating that receptor reg-
ulation of the fused G-protein is not su⁄cient to promote
e¡ector regulation. It is unclear why the fusions fail to regu-
late e¡ector pathways in the presence of pertussis toxin. How-
ever, in a similar study a fusion between the K2A-adrenoceptor
and Cys351Gly Gi1K was unable to regulate adenylyl cyclase
and MAP kinase following stable expression in Rat1 ¢bro-
blasts [9].
The inability of the fusions to regulate adenylyl cyclase
could be explained if the G-protein within the fusion is re-
strained from interacting with this enzyme. However the ab-
sence of receptor regulation of MAP kinase is surprising as
GPCR regulation of MAP kinase is thought to be a conse-
quence of the regulation of ras/raf by the G-protein LQ com-
plex [15^17]. While we have not shown that these fusions are
able to functionally interact with LQ it is known that an K2A-
adrenoceptor/Cys351Gly Gi1K fusion protein is able to bind
LQ [18]. An explanation may be that GiK regulation of MAP
kinase requires e¡ector regulation by both the GK and the LQ
to subunits.
In conclusion we demonstrate the functional characterisa-
tion of the ¢rst fusion between a GPCR, GFP and a G-pro-
tein K subunit. Inclusion of GFP within the fusion creates an
intrinsically £uorescent receptor, which binds ligand with sim-
ilar a⁄nity to the wild-type receptor and remains capable of
functional interaction with endogenously expressed G-protein.
Furthermore the inclusion of GFP facilitates functional inter-
action of the receptor with the fused G-protein. We expect
that the inclusion of GFP within receptor/G-protein fusion
proteins will expand the utility of such fusions in studies de-
signed to understand the complexities of GPCR signalling,
tra⁄cking, desensitisation and internalisation.
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